UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

The UK prescription pharmaceutical market was valued at $18.1 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total healthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.

UK: criticism mounts over NHS reform but pharmaceutical firms may benefit

The UK coalition government is facing legal action from public services trade union UNISON over plans to shake up the National Health Service in a bid to find efficiency savings. However, the proposed reforms could benefit pharmaceutical companies, with patients gaining access to drugs previously blocked by the health service's cost watchdog.

Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

US: industry skeptical of new US drug safety bill despite record recalls

Additional drug safety responsibilities could be placed on pharmaceutical companies with the introduction of a new US bill in the Senate. The bill, which comes in the wake of record product recalls, aims to strengthen manufacturing standards and better equip the FDA to oversee the pharmaceutical supply chain. However, if passed, the legislation would create considerable costs for drug makers.

Multiple Sclerosis - Next generation therapies signal the start of a new era

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (2009/2019).

Trends in Generics Industry Ownership: Evaluating changing industry paradigms and emerging players

Startups & other generic drug companies are attempting to expand, seeking capital in China, Latin America & other regions are privatizing. This report examines these ownership structures in the context of current & future industry trends, discussing current best practices through nine case studies & examining which ownership structures are most effective for which types of situations.

Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates

This report explains what therapeutic vaccines are, how they work, and why drug developers around the world are using this approach to address everything from allergies to literally every kind of cancer. More than 70 new proprietary technologies are named and explained, with details of licensing deals and intellectual property positions.

The Cardiovascular Market Outlook to 2015:Competitive landscape, global market analysis, key trends and pipeline analysis

This report provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players.

News Release - July 22, 2010
Evolution Summit 2010 Summit 2010
Fairmont Le Montreux Palace, Montreux, Switzerland, 27 - 29 October 2010
http://www.evolution-summit.com/FarmavitaPR

Interview with: Maha Al Farhan, President & Chief Executive Officer, ClinArt

Maha Al Farhan from ClinArt, a sponsor at the marcus evans Evolution Summit 2010, shares her thoughts on overcoming reporting challenges through better communication.

Reporting information to health authorities in an accurate and timely manner is a top priority, as well as a challenge, for Chief Medical Officers (CMOs) of clinical trials. When patient health is at risk, no chances can be taken. CMOs can ease the reporting process by establishing healthy communication channels between the different parties, and making use of innovative software solutions, says Maha Al Farhan, President and Chief Executive Officer at ClinArt. From a sponsor company at the marcus evans Evolution Summit 2010 taking place in Switzerland, 27 - 29 October, Al Farhan discusses reporting best practices, and healthy communication strategies.

Sydney, Australia, July 30, 2010

GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Aricept® (Donepezil), the world's best selling anti-Alzheimer's drug developed by Eisai and co-marketed with Pfizer. The article analyses the patent landscape surrounding Donepezil, highlighting the need for comprehensive patent information in the development of launch strategies for generic products to minimise the risk of litigation.

Pharma Marketing 2010

Frankfurt, September 30th, 2010

Pharma Marketing 2010 provides a key platform for Europe's pharmaceutical industry stakeholders, such as yourself, to discover how best to tackle the key challenges of a price-sensitive and increasingly competitive and rapidly changing market.While spending power is decreasing across the globe, companies face intensifying pressure to do more with fewer resources.

MENA Oncology Conference

22nd and 23rd October 2010, Cairo, Egypt 

"Fleming Gulf's MENA Oncology Conference has been organized as a result of the rising incidence of breast cancer in the MENA (Middle-Ease and North-African) region, and seeks to bring this disease to the forefront of public awareness and discussion. Breast cancer, despite all medical and technological advances, has been on the rise in the last 50 years or so and is expected to be diagnosed in 25 million women over the next 25 years, with incidence rates climbing in developing countries. In many parts of the world outside of the U.S. and Western Europe, awareness of the disease remains low, ultimately resulting in higher mortality rates.

2^nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models

14th-15th September, 2010
Washington DC, USA

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health plans, health technology assessment (HTA) & physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increase in the range of expensive drugs and technologies available as potential therapies. In light of this, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

2^nd Annual Pharmaceutical Market & Patient Access for Chronic Disease Therapies

15th-16th September, 2010
Brussels, Belgium

Chronic diseases are taking a steadily increasing share of national health spending in the developed world, especially due to an ageing population and unhealthy lifestyles. Such conditions and treatments do not often seem as controversial and as high on the political, healthcare system and media‘s agenda, when compared to the very expensive cancer or orphan drugs, for example. Typically, drugs for chronic diseases are priced at very reasonable levels, yet are making a large budget impact, effecting significant percentages of the entire population.  

Evolution Summit 2010

27-29 October 2010, Fairmont Le Montreux Palace, Montreux, Switzerland

The Multi-Dimensional Challenges of Market Access

Gerard Klop from Vintura, a sponsor at the marcus evans PharmaBrand Summit 2010, discusses how best to tackle the market access issues facing pharmaceutical companies today.

Monte-Carlo, Monaco, June 21, 2010 

The name of the game is early stakeholder involvement and internal and external collaboration, says Gerard Klop, Managing Partner at Vintura. Pharmaceutical marketing directors must look for capabilities inside and outside their organisation, as the industry has shifted to a multi- stakeholder, channel and proposition environment, and become very dynamic in nature. Solving everything within their own department would not address the multi-dimensional aspects of the problem, would take too much time to develop and would not create the flexibility to adapt quickly to the ever changing environment. As a sponsor at the marcus evans PharmaBrand Summit 2010, taking place in Monaco, 21 - 23 June, Klop highlights why adopting collaborative models is the way to go.

The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

This report provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. This report reviews the factors and underlying trends that are currently shaping market development.

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.